- "We completed a yearlong development project to create a unique and patent pending offering to the dye sublimation market. We have a strong domestic distributor who is planning a major launch of this technology this fall. This is a new market for IKONICS and a new technology for the industry. We believe the sales potential is $10 million worldwide with the market growing at a rate of 20% annually according to a 2016 industry survey.
- "Our major aerospace customer began re-ordering, with the first shipment occurring in July. The customer has indicated that orders will continue on pace with the second half of last year, and we are adding other new aerospace customers."
- "In the second quarter our automotive DTX business sold two inkjet printers, including one to an industry leader, with a third sale pending. Printer sales drive profitable sales of our patented substrates."
- "For the year our worldwide sales of screen print chemicals were essentially flat, with new distribution in China being an important contributor. IKONICS Imaging sales were down 9% year over year. I expect that new sales to the dye sublimation market will contribute to another growth year for IKONICS Imaging.
IKONICS also announced that its board of directors approved a share repurchase authorization for an additional 100,000 shares of the company's common stock. This share repurchase authorization replaces all prior authorizations. Repurchases may be completed from time to time in the open market or in privately negotiated transactions, subject to applicable laws and regulations. This authorization does not have an expiration date.This press release contains forward-looking statements regarding sales, gross profits, net earnings (losses), balance sheet position, industry trends, customer agreements, new products, technologies, markets and business initiatives that involve risks and uncertainties. The Company's actual results could differ materially as a result of downturns in the aerospace industry, unexpected production delays by the Company's customers, lack of acceptance of new products and technologies, failure of customers to enter into anticipated agreements, introduction of new products or technologies by competitors, domestic and global economic conditions, inherent risk and uncertainty in the protection of intellectual property rights, the ability to control operating costs without impacting growth as well as the factors described in the Company's Forms 10-K, and 10-Q, and other reports on file with the SEC.
|CONDENSED STATEMENTS OF OPERATIONS (Unaudited)|
|For the Three and Six Months Months Ended June 30, 2017 and 2016|
|Three Months Ended||Six Months Ended|
|Cost of goods sold||3,242,097||2,674,367||5,780,861||5,390,903|
|Income (loss) from operations||(135,076||)||49,916||(721,232||)||(270,390||)|
|Income (loss) before income taxes||(150,000||)||36,965||(751,820||)||(283,227||)|
|Income tax benefit||(44,934||)||(2,260||)||(267,857||)||(129,640||)|
|Net Income (loss)||$||(105,066||)||$||39,225||$||(483,963||)||$||(153,587||)|
|Income (loss) per common share-basic and diluted||$||(0.05||)||$||0.02||$||(0.24||)||$||(0.08||)|
|Average diluted shares outstanding||2,018,466||2,018,833||2,018,609||2,018,544|
|Condensed Balance Sheets|
|As of June 30, 2017 and December 31, 2016|
|Property, plant, and equipment, net||8,625,069||8,912,395|
|Intangible assets, net||340,211||338,127|
|Liabilities and Stockholders' Equity|
|Deferred income taxes||446,000||446,000|
|CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)|
|For the Six Months Ended June 30, 2017 and 2016|
|Net cash provided by operating activities||$||50,513||$||528,208|
|Net cash provided by (used in) investing activities||223,577||(5,244,274||)|
|Net cash provided by (used in) financing activities||(82,717||)||3,268,489|
|Net increase (decrease) in cash and cash equivalents||191,373||(1,447,577||)|
|Cash and cash equivalents at beginning of period||1,048,713||2,248,466|
|Cash and cash equivalents at end of period||$||1,240,086||$||800,889|
News Contact: Bill Ulland Chairman, President & CEO (218) 628-2217